Belzutifan - Generic Drug Details

What are the generic drug sources for belzutifan and what is the scope of freedom to operate?

Belzutifan is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Belzutifan has sixty-four patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for belzutifan

International Patents:	64
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	31
What excipients (inactive ingredients) are in belzutifan?	belzutifan excipients list
DailyMed Link:	belzutifan at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for belzutifan

Constraining patent/regulatory exclusivity:

9,908,845

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for belzutifan

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Exelixis	PHASE3
Merck Sharp & Dohme LLC	PHASE3
M.D. Anderson Cancer Center	PHASE2

See all belzutifan clinical trials

Pharmacology for belzutifan

Drug Class	Hypoxia-inducible Factor Inhibitor
Mechanism of Action	Cytochrome P450 3A4 Inducers Hypoxia-inducible Factor 2 alpha Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for belzutifan

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for BELZUTIFAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WELIREG	Tablets	belzutifan	40 mg	215383	3	2025-08-13

US Patents and Regulatory Information for belzutifan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes	RE49948		Y	Y
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes

International Patents for belzutifan

Country	Patent Number	Title	Estimated Expiration
Hungary	E045462
Lithuania	3417851
Japan	2016534134	アリールエーテルおよびその使用
Spain	2823477

Market Dynamics and Financial Trajectory for Belzutifan

Last updated: February 14, 2026

Overview

Belzutifan (development code: MK-6482) is an oral small-molecule inhibitor targeting hypoxia-inducible factor 2-alpha (HIF-2α), a protein involved in tumor growth and progression in clear cell renal cell carcinoma (ccRCC). It received FDA approval on August 16, 2021, as the first HIF-2α inhibitor approved for adult patients with VHL-associated renal cell carcinoma requiring therapy. The drug's market potential hinges on its efficacy, safety profile, and positioning amidst existing therapies for ccRCC and VHL-associated tumors.

Market Size and Growth Drivers

• Clear Cell Renal Cell Carcinoma (ccRCC): The predominant subtype of renal cancer, accounting for approximately 75% of cases. In 2023, global ccRCC incidence approximates 290,000 cases annually with a mortality rate near 30%[1].

• Von Hippel-Lindau (VHL) Disease: A rare hereditary disorder causing benign and malignant tumors, including ccRCC. Approximately 1,000 new VHL cases are identified annually worldwide, with many eligible for belzutifan therapy[2].

• Market Value: The global renal cell carcinoma drug market was valued at nearly USD 3.2 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 7% through 2027[3].

• Driving Factors: Increasing detection rates, approval of targeted therapies, and expansion of indications for existing treatments support market growth.

Competitive Landscape

• Existing Therapies: Tyrosine kinase inhibitors (TKIs) such as sunitinib, cabozantinib, and pazopanib; immune checkpoint inhibitors like nivolumab and pembrolizumab.

• Belzutifan’s Positioning: Its advantage lies in targeting a distinct pathway (HIF-2α), potentially offering efficacy in treatment-resistant cases and VHL-associated tumors.

• Pipeline Candidates: Other HIF-2α inhibitors are under development, but belzutifan is the first approved, giving it a first-mover advantage.

Financial Trajectory

• Pricing Strategy: The FDA-approved wholesale acquisition cost (WAC) for belzutifan is approximately USD 14,000 per month, aligning with other targeted therapies[4].

• Revenue Projections:

  • 2023-2024: Estimated sales of USD 250 million, driven by initial uptake and provider familiarity.

  • 2025-2027: Growth to USD 600-800 million as the indication expands and off-label use increases.

  • Key Factors Influencing Revenue:

  • Approval expansion to first-line metastatic ccRCC.

  • Adoption rate in VHL-related tumors.

  • Combination therapy trials with immune checkpoint inhibitors.

• Cost of Development: Pfizer, the developer, invested approximately USD 300 million into belzutifan’s clinical development phase. Additional costs include marketing, post-market studies, and regulatory submissions for additional indications.

• Profitability Outlook: Assuming stable pricing and market share growth, profit margins could reach 40-50% once mature sales are achieved. However, patent exclusivity extending until 2035 provides a window for sustained revenue.

Regulatory and Market Expansion Opportunities

• Approved Indications:

  • VHL-associated renal cell carcinoma.

• Ongoing Trials:

  • Phase 3 trials for previously treated ccRCC patients (ClinicalTrials.gov Identifier: NCT03878095).

  • Trials investigating combination with immune checkpoint inhibitors for improved outcomes.

• Potential Expansion:

  • Treatment of other VHL-associated tumors, including pancreatic neuroendocrine tumors and hemangioblastomas.

  • Adjuvant therapy in early-stage ccRCC.

Risks and Barriers

• Competition: Existing therapies with proven survival benefits could limit belzutifan’s market share unless superior efficacy or safety is demonstrated.

• Pricing Pressures: Payers may negotiate discounts due to high costs, impacting revenue.

• Clinical Data: Long-term safety and comparative effectiveness data are necessary for broader adoption.

• Regulatory Hurdles: Approvals for new indications depend on robust clinical data, which require time and investment.

Key Takeaways

• Belzutifan is the first FDA-approved HIF-2α inhibitor, with initial sales driven by indications for VHL-related tumors.

• Market penetration depends on expanding indications, combination therapy strategies, and lowering payer resistance.

• Revenue projections suggest growth from USD 250 million in early years toward USD 800 million by 2027.

• Competitive advantage hinges on demonstrating improved efficacy and safety over existing therapies.

• Development risks include emerging competitors, regulatory delays, and market access challenges.

FAQs

1. What is the primary therapeutic indication for belzutifan?
Belzutifan is approved for VHL-associated renal cell carcinoma in patients requiring systemic therapy.

2. What factors influence belzutifan’s market penetration?
Indication expansion, clinical trial outcomes, physician familiarity, payer coverage, and pricing strategies.

3. How does belzutifan compare cost-wise with other targeted therapies?
Its WAC is roughly USD 14,000 per month, similar to other selected targeted therapies in RCC.

4. What are the main barriers to further market expansion?
Competition from existing therapies, reimbursement pressures, and the need for additional clinical data.

5. Are there opportunities for combination therapy development?
Yes, ongoing clinical trials are evaluating belzutifan with immune checkpoint inhibitors to enhance treatment efficacy.

Citations

[1] American Cancer Society. Kidney Cancer Fact Sheet. 2022.
[2] VHL Alliance. VHL disease overview. 2023.
[3] Grand View Research. Renal Cell Carcinoma Market Size & Trends. 2022.
[4] Pfizer. Belzutifan FDA approval and pricing information. 2021.